Evaluation of the performance of novel Aβ isoforms as theragnostic markers in Alzheimer's disease: from the cell to the patient.

• Alzheimer's disease (AD) is the most common neurodegenerative disorder in the aging population and is characterized by extracellular plaques in the brain. The last decades have witnessed an explosion in studies of the role of amyloid-β (Aβ) metabolism and aggregation in the pathogenesis of AD which has been translated into novel promising therapies with putative disease-modifying effects.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Neurosciences (hsv//eng)

Nyckelord

Alanine

analogs & derivatives

pharmacology

Alzheimer Disease

cerebrospinal fluid

Amyloid Precursor Protein Secretases

drug effects

Amyloid beta-Peptides

cerebrospinal fluid

immunology

Animals

Antibodies

Monoclonal

metabolism

Azepines

pharmacology

Dogs

Enzyme Inhibitors

pharmacology

Humans

Immunoprecipitation

Mice

Protein Isoforms

cerebrospinal fluid

Spectrometry

Mass

Matrix-Assisted Laser Desorption-Ionization

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)